The no-reflow phenomenon in the coronary circulation

Cardiovascular and Hematological Agents in Medicinal Chemistry

Volumn 7, Issue 3, 2009, Pages 181-192

  Kiernan, Thomas J ^a   Ruggiero II, Nicholas J ^a   Bernal, Juan M ^a   Don, Creighton W ^a   Witzke, Christian ^a   Kiernan, Gareth D ^b   Cubeddu, Roberto J ^a   Yan, Bryan P ^c,d  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b UNIVERSITY COLLEGE DUBLIN   (Ireland)

^c CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^d CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ADENOSINE; ADRENALIN; CLAZOSENTAN; DILTIAZEM; ENDOTHELIN 1; ENDOTHELIN A RECEPTOR ANTAGONIST; ENDOTHELIN B RECEPTOR ANTAGONIST; FIBRINOGEN RECEPTOR ANTAGONIST; FIBRINOLYTIC AGENT; GLYCERYL TRINITRATE; NICARDIPINE; NICORANDIL; NITINOL; NITROPRUSSIDE SODIUM; NORADRENALIN; PLACEBO; SEROTONIN; VERAPAMIL;

ACUTE CORONARY SYNDROME; ACUTE HEART INFARCTION; ADJUVANT THERAPY; ANGIOCARDIOGRAPHY; ARTERY EMBOLISM; ATRIOVENTRICULAR BLOCK; BALLOON OCCLUSION; BARE METAL STENT; BLEEDING; BLOOD FILTER; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CORONARY ARTERY BLOOD FLOW; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG MEGADOSE; DRUG POTENTIATION; HEART ASSIST DEVICE; HEART BLOCK; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; HYPOTENSION; INTERMETHOD COMPARISON; INTRAVASCULAR ULTRASOUND; NO REFLOW PHENOMENON; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PERCUTANEOUS CORONARY INTERVENTION; REPERFUSION; REVIEW; ST SEGMENT ELEVATION; THROMBOCYTE AGGREGATION; THROMBOEMBOLISM; THROMBOSIS; VASCULAR ACCESS DEVICE; VASOSPASM;

ADENOSINE; ANIMALS; CORONARY CIRCULATION; DILTIAZEM; HUMANS; NICARDIPINE; NICORANDIL; NITROPRUSSIDE; NO-REFLOW PHENOMENON; PROSTHESES AND IMPLANTS; VASODILATOR AGENTS; VERAPAMIL;

EID: 70349511904     PISSN: 18715257     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152509789105426     Document Type: Review

References (114)

1. Kloner, R.A.; Ganote, C.E.; Jennings, R.B. The "no-reflow" phenomenon after temporary coronary occlusion in the dog. J. Clin. Invest., 1974, 54, 1496.
2. Piana, R.N.; Paik, G.Y.; Moscucci, M.; Cohen, D.J.; Gibson, C.M.; Kugelmass, A.D.; Carrozza, J.P., Jr.; Kuntz, R.E.; Baim, D.S. Incidence and treatment of 'no-reflow' after percutaneous coronary intervention. Circulation, 1994, 89, 2514.
3. Eeckhout, E.; Kern, M.J. The coronary no-reflow phenomenon: a review of mechanisms and therapies. Eur. Heart J., 2001, 22, 729.
4. Abbo, K.M.; Dooris, M.; Glazier, S.; O'Neill, W.W.; Byrd, D.; Grines, C.L.; Safian, R.D. Features and outcome of no-reflow after percutaneous coronary intervention. Am. J. Cardiol., 1995, 75, 778.
5. Ito, H.; Maruyama, A.; Iwakura, K.; Takiuchi, S.; Masuyama, T.; Hori, M.; Higashino, Y.; Fujii, K.; Minamino, T. Clinical implications of the 'no reflow' phenomenon. A predictor of complications and left ventricular remodeling in reperfused anterior wall myocardial infarction. Circulation, 1996, 93, 223.
6. Fischell, T.A.; Maheshwari, A. Current applications for nicardipine in invasive and interventional cardiology. J. Invasive Cardiol., 2004, 16, 428.
7. Ito, H.; Tomooka, T.; Sakai, N.; Yu, H.; Higashino, Y.; Fujii, K.; Masuyama, T.; Kitabatake, A.; Minamino, T. Lack of myocardial perfusion immediately after successful thrombolysis. A predictor of poor recovery of left ventricular function in anterior myocardial infarction. Circulation, 1992, 85, 1699.
8. Yip, H.K.; Chen, M.C.; Chang, H.W.; Hang, C.L.; Hsieh, Y.K.; Fang, C.Y.; Wu, C.J. Angiographic morphologic features of infarct-related arteries and timely reperfusion in acute myocardial infarction: predictors of slow-flow and no-reflow phenomenon. Chest, 2002, 122, 1322.
9. Falk, E.; Thuesen, L. Pathology of coronary microembolisation and no reflow. Heart, 2003, 89, 983.
10. Reffelmann, T.; Kloner, R.A. The "no-reflow" phenomenon: basic science and clinical correlates. Heart, 2002, 87, 162.
11. Reffelmann, T.; Kloner, R.A. Microvascular reperfusion injury: rapid expansion of anatomic no reflow during reperfusion in the rabbit. Am. J. Physiol. Heart Circ. Physiol., 2002, 283, H1099.
12. Okamura, A.; Ito, H.; Iwakura, K.; Kawano, S.; Inoue, K.; Maekawa, Y.; Ogihara, T.; Fujii, K. Detection of embolic particles with the Doppler guide wire during coronary intervention in patients with acute myocardial infarction: efficacy of distal protection device. J. Am. Coll. Cardiol., 2005, 45, 212.
13. Kalan, J.M.; Roberts, W.C. Morphologic findings in saphenous veins used as coronary arterial bypass conduits for longer than 1 year: necropsy analysis of 53 patients, 123 saphenous veins, and 1865 five-millimeter segments of veins. Am. Heart J., 1990, 119, 1164.
14. Gawaz, M. Role of platelets in coronary thrombosis and reperfusion of ischemic myocardium. Cardiovasc. Res., 2004, 61, 498.
15. Kahn, J.K.; Rutherford, B.D.; McConahay, D.R.; Johnson, W.L.; Giorgi, L.V.; Shimshak, T.M.; Ligon, R.W.; Hartzler, G.O. Initial and long-term outcome of 83 patients after balloon angioplasty of totally occluded bypass grafts. J. Am. Coll. Cardiol., 1994, 23, 1038.
16. Salloum, J.; Tharpe, C.; Vaughan, D.; Zhao, D.X. Release and elimination of soluble vasoactive factors during percutaneous coronary intervention of saphenous vein grafts: analysis using the PercuSurge GuardWire distal protection device. J. Invasive Cardiol., 2005, 17, 575.
17. Barrabes, J.A.; Garcia-Dorado, D.; Mirabet, M.; Inserte, J.; Agullo, L.; Soriano, B.; Massaguer, A.; Padilla, F.; Lidon, R.M.; Soler-Soler, J. Antagonism of selectin function attenuates microvascular platelet deposition and platelet-mediated myocardial injury after transient ischemia. J. Am. Coll. Cardiol., 2005, 45, 293.
18. Edgington, T.S.; Mackman, N.; Brand, K.; Ruf, W. The structural biology of expression and function of tissue factor. Thromb. Haemost., 1991, 66, 67.
19. Carson, S.D.; Brozna, J.P. The role of tissue factor in the production of thrombin. Blood Coagul. Fibrinolysis, 1993, 4, 281.
20. Nemerson, Y. Tissue factor: then and now. Thromb. Haemost., 1995, 74, 180.
21. Mallat, Z.; Hugel, B.; Ohan, J.; Leseche, G.; Freyssinet, J.M.; Tedgui, A. Shed membrane microparticles with procoagulant potential in human atherosclerotic plaques: a role for apoptosis in plaque thrombogenicity. Circulation, 1999, 99, 348.
22. Thiruvikraman, S.V.; Guha, A.; Roboz, J.; Taubman, M.B.; Nemerson, Y.; Fallon, J.T. In situ localization of tissue factor in human atherosclerotic plaques by binding of digoxigenin-labeled factors VIIa and X. Lab. Invest., 1996, 75, 451.
23. Marmur, J.D.; Thiruvikraman, S.V.; Fyfe, B.S.; Guha, A.; Sharma, S.K.; Ambrose, J.A.; Fallon, J.T.; Nemerson, Y.; Taubman, M.B. Identification of active tissue factor in human coronary atheroma. Circulation, 1996, 94, 1226.
24. Tremoli, E.; Camera, M.; Toschi, V.; Colli, S. Tissue factor in atherosclerosis. Atherosclerosis, 1999, 144, 273.
25. Bonderman, D.; Teml, A.; Jakowitsch, J.; Adlbrecht, C.; Gyongyosi, M.; Sperker, W.; Lass, H.; Mosgoeller, W.; Glogar, D.H.; Probst, P.; Maurer, G.; Nemerson, Y.; Lang, I.M. Coronary no-reflow is caused by shedding of active tissue factor from dissected atherosclerotic plaque. Blood, 2002, 99, 2794.
26. Funayama, H.; Ishikawa, S.E.; Sugawara, Y.; Kubo, N.; Momomura, S.I.; Kawakami, M. Myeloperoxidase may contribute to the no-reflow phenomenon in patients with acute myocardial infarction. Int. J. Cardiol., 2009.
27. Sdringola, S.; Assali, A.R.; Ghani, M.; Moustapha, A.; Achour, H.; Yusuf, S.W.; Fujise, K.; Rosales, O.; Schroth, G.W.; Anderson, H.V.; Smalling, R.W. Risk assessment of slow or no-reflow phenomenon in aortocoronary vein graft percutaneous intervention. Catheter Cardiovasc. Interv., 2001, 54, 318.
28. Ito, H.; Maruyama, A.; Iwakura, K.; Takiuchi, S.; Masuyama, T.; Hori, M.; Higashino, Y.; Fujii, K.; Minamino, T. Clinical implications of the 'no reflow' phenomenon. A predictor of complications and left ventricular remodeling in reperfused anterior wall myocardial infarction. Circulation, 1996, 93, 223.
29. Romano, M.; Buffoli, F.; Lettieri, C.; Aroldi, M.; Tomasi, L.; Baccaglioni, N.; Rosiello, R.; Zanini, R. No reflow in patients undergoing primary angioplasty for acute myocardial infarction at high risk: incidence and predictive factors. Minerva Cardioangiol., 2005, 53, 7.
30. Kirma, C.; Izgi, A.; Dundar, C.; Tanalp, A. C.; Oduncu, V.; Aung, S.M.; Sonmez, K.; Mutlu, B.; Ozdemir, N.; Erentug, V. Clinical and procedural predictors of no-reflow phenomenon after primary percutaneous coronary interventions: experience at a single center. Circ. J., 2008, 72, 716.
31. Hara, M.; Saikawa, T.; Tsunematsu, Y.; Sakata, T.; Yoshimatsu, H. Predicting no-reflow based on angiographic features of lesions in patients with acute myocardial infarction. J. Atheroscler. Thromb., 2005, 12, 315.
32. Waksman, R.; Weintraub, W.S.; Ghazzal, Z.; Scott, N.A.; Shen, Y.; King, S.B., 3rd; Douglas, J.S., Jr. Short- and long-term outcome of narrowed saphenous vein bypass graft: a comparison of Palmaz-Schatz stent, directional coronary atherectomy, and balloon angioplasty. Am. Heart J., 1997, 134, 274.
33. Bhargava, B.; Kornowski, R.; Mehran, R.; Kent, K.M.; Hong, M.K.; Lansky, A.J.; Waksman, R.; Pichard, A.D.; Satler, L.F.; Leon, M.B. Procedural results and intermediate clinical outcomes after multiple saphenous vein graft stenting. J. Am. Coll. Cardiol., 2000, 35, 389.
34. Romano, M.; Buffoli, F.; Tomasi, L.; Aroldi, M.; Lettieri, C.; Ferrari, M.R.; Zanini, R. The no-reflow phenomenon in acute myocardial infarction after primary angioplasty: incidence, predictive factors, and long-term outcomes. J. Cardiovasc. Med. (Hagerstown), 2008, 9, 59.
35. Yip, H.K.; Chen, M.C.; Chang, H.W.; Hang, C.L.; Hsieh, Y.K.; Fang, C.Y.; Wu, C.J. Angiographic morphologic features of infarct-related arteries and timely reperfusion in acute myocardial infarction: predictors of slow-flow and no-reflow phenomenon. Chest, 2002, 122, 1322.
36. Maden, O.; Kacmaz, F.; Selcuk, M.T.; Selcuk, H.; Alyan, O.; Aksu, T.; Metin, F.; Tufekcioglu, O.; Atak, R.; Demir, A.D.; Balbay, Y.; Ilkay, E. Relation of admission QRS duration with development of angiographic no-reflow in patients with acute ST-segment elevation myocardial infarction treated with primary percutaneous interventions. J. Electrocardiol., 2008, 41, 72.
37. Iwakura, K.; Ito, H.; Kawano, S.; Okamura, A.; Kurotobi, T.; Date, M.; Inoue, K.; Fujii, K. Chronic pre-treatment of statins is associated with the reduction of the no-reflow phenomenon in the patients with reperfused acute myocardial infarction. Eur. Heart J., 2006, 27, 534.
38. Iwakura, K.; Ito, H.; Kawano, S.; Shintani, Y.; Yamamoto, K.; Kato, A.; Ikushima, M.; Tanaka, K.; Kitakaze, M.; Hori, M.; Higashino, Y.; Fujii, K. Predictive factors for development of the no-reflow phenomenon in patients with reperfused anterior wall acute myocardial infarction. J. Am. Coll. Cardiol., 2001, 38, 472.
39. Tanaka, A.; Kawarabayashi, T.; Nishibori, Y.; Sano, T.; Nishida, Y.; Fukuda, D.; Shimada, K.; Yoshikawa, J. No-reflow phenomenon and lesion morphology in patients with acute myocardial infarction. Circulation, 2002, 105, 2148.
40. Iwakura, K.; Ito, H.; Kawano, S.; Okamura, A.; Tanaka, K.; Nishida, Y.; Maekawa, Y.; Masuyama, T.; Hori, M.; Fujii, K. Prediction of the no-reflow phenomenon with ultrasonic tissue characterization in patients with anterior wall acute myocardial infarction. Am. J. Cardiol., 2004, 93, 1357.
41. Prasad, A.; Stone, G.W.; Stuckey, T.D.; Costantini, C.O.; Mehran, R.; Garcia, E.; Tcheng, J.E.; Cox, D.A.; Grines, C.L.; Lansky, A.J.; Gersh, B.J. Relation between leucocyte count, myonecrosis, myocardial perfusion, and outcomes following primary angioplasty. Am. J. Cardiol., 2007, 99, 1067.
42. Hong, S.N.; Ahn, Y.; Hwang, S.H.; Yoon, N.S.; Lee, S.R.; Moon, J.Y.; Kim, K.H.; Hong, Y.J.; Park, H.W.; Kim, J.H.; Jeong, M.H.; Cho, J.G.; Park, J.C.; Kang, J.C. Usefulness of preprocedural N-terminal pro-brain natriuretic peptide in predicting angiographic no-reflow phenomenon during stent implantation in patients with ST-segment elevation acute myocardial infarction. Am. J. Cardiol., 2007, 100, 631.
43. Iwakura, K.; Ito, H.; Ikushima, M.; Kawano, S.; Okamura, A.; Asano, K.; Kuroda, T.; Tanaka, K.; Masuyama, T.; Hori, M.; Fujii, K. Association between hyperglycemia and the no-reflow phenomenon in patients with acute myocardial infarction. J. Am. Coll. Cardiol., 2003, 41, 1.
44. Zhao, J.L.; Yang, Y.J.; Zhang, Y.H.; Pei, W.D.; Sun, Y.H.; Chen, J.L.; Gao, R.L. Chronic pretreatment of ACEI reduces no-reflow in patients with acute myocardial infarction treated with primary angioplasty. Clin. Cardiol., 2007, 30, 130.
45. Jesel, L.; Morel, O.; Ohlmann, P.; Germain, P.; Faure, A.; Jahn, C.; Coulbois, P.M.; Chauvin, M.; Bareiss, P.; Roul, G. Role of pre-infarction angina and inflammatory status in the extent of microvascular obstruction detected by MRI in myocardial infarction patients treated by PCI. Int. J. Cardiol., 2007, 121, 139.
46. Bae, J.H.; Kwon, T.G.; Hyun, D.W.; Rihal, C.S.; Lerman, A. Predictors of slow flow during primary percutaneous coronary intervention: an intavascular ultrasound-virtual histology study. Heart, 2008, 94(12), 1559.
47. Watanabe, T.; Nanto, S.; Uematsu, M.; Ohara, T.; Morozumi, T.; Kotani, J.; Nishio, M.; Awata, M.; Nagata, S.; Hori, M. Prediction of no-reflow phenomenon after successful percutaneous coronary intervention in patients with acute myocardial infarction: intravascular ultrasound findings. Circ. J., 2003, 67, 667.
48. Resnic, F.S.; Wainstein, M.; Lee, M.K.; Behrendt, D.; Wainstein, R.V.; Ohno-Machado, L.; Kirshenbaum, J.M.; Rogers, C.D.; Popma, J.J.; Piana, R. No-reflow is an independent predictor of death and myocardial infarction after percutaneous coronary intervention. Am. Heart J., 2003, 145, 42.
49. Di Carli, M.F.; Janisse, J.; Grunberger, G.; Ager, J. Role of chronic hyperglycemia in the pathogenesis of coronary microvascular dys-function in diabetes. J. Am. Coll. Cardiol., 2003, 41, 1387.
50. Miura, H.; Wachtel, R.E.; Loberiza, F.R., Jr.; Saito, T.; Miura, M.; Nicolosi, A.C.; Gutterman, D.D. Diabetes mellitus impairs vasodilation to hypoxia in human coronary arterioles: reduced activity of ATP-sensitive potassium channels. Circ. Res., 2003, 92, 151.
51. Lee, C.H.; Teo, S.G.; Hong, E.; Wong, H.B.; Low, A.; Sutandar, A.; Tan, H.C.; Lim, Y.T. Impact of glycemic control on occurrence of no-reflow and 30-day outcomes in diabetic patients undergoing primary angioplasty for myocardial infarction. J. Invasive Cardiol., 2005, 17, 422.
52. Iijima, R.; Shinji, H.; Ikeda, N.; Itaya, H.; Makino, K.; Funatsu, A.; Yokouchi, I.; Komatsu, H.; Ito, N.; Nuruki, H.; Nakajima, R.; Nakamura, M. Comparison of coronary arterial finding by intravascular ultrasound in patients with "transient no-reflow" versus "reflow" during percutaneous coronary intervention in acute coronary syndrome. Am. J. Cardiol., 2006, 97, 29.
53. Kotani, J.; Nanto, S.; Mintz, G.S.; Kitakaze, M.; Ohara, T.; Morozumi, T.; Nagata, S.; Hori, M. Plaque gruel of atheromatous coronary lesion may contribute to the no-reflow phenomenon in patients with acute coronary syndrome. Circulation, 2002, 106, 1672.
54. Bonetti, P.O.; Wilson, S.H.; Rodriguez-Porcel, M.; Holmes, D.R., Jr.; Lerman, L.O.; Lerman, A. Simvastatin preserves myocardial perfusion and coronary microvascular permeability in experimental hypercholesterolemia independent of lipid lowering. J. Am. Coll. Cardiol., 2002, 40, 546.
55. Wassmann, S.; Laufs, U.; Baumer, A.T.; Muller, K.; Ahlbory, K.; Linz, W.; Itter, G.; Rosen, R.; Bohm, M.; Nickenig, G. HMG-CoA reductase inhibitors improve endothelial dysfunction in normocholesterolemic hypertension via reduced production of reactive oxygen species. Hypertension, 2001, 37, 1450.
56. Kojima, S.; Sakamoto, T.; Ishihara, M.; Kimura, K.; Miyazaki, S.; Tei, C.; Hiraoka, H.; Sonoda, M.; Tsuchihashi, K.; Yamagishi, M.; Inoue, T.; Asada, Y.; Ikeda, Y.; Shirai, M.; Ogawa, H. The white blood cell count is an independent predictor of no-reflow and mortality following acute myocardial infarction in the coronary interventional era. Ann. Med., 2004, 36, 153.
57. Celik, T.; Iyisoy, A.; Kursaklioglu, H.; Turhan, H.; Kilic, S.; Kose, S.; Amasyali, B.; Isik, E. The impact of admission C-reactive protein levels on the development of poor myocardial perfusion after primary percutaneous intervention in patients with acute myocardial infarction. Coron. Artery Dis., 2005, 16, 293.
58. Huczek, Z.; Kochman, J.; Filipiak, K.J.; Horszczaruk, G.J.; Grabowski, M.; Piatkowski, R.; Wilczynska, J.; Zielinski, A.; Meier, B.; Opolski, G. Mean platelet volume on admission predicts impaired reperfusion and long-term mortality in acute myocardial infarction treated with primary percutaneous coronary intervention. J. Am. Coll. Cardiol., 2005, 46, 284.
59. Brown, N.J.; Vaughan, D.E. Angiotensin-converting enzyme inhibitors. Circulation, 1998, 97, 1411.
60. Enseleit, F.; Hurlimann, D.; Luscher, T.F. Vascular protective effects of angiotensin converting enzyme inhibitors and their relation to clinical events. J. Cardiovasc. Pharmacol., 2001, 37(Suppl. 1), S21.
61. Burzotta, F.; Trani, C.; Romagnoli, E.; Mazzari, M.A.; Rebuzzi, A.G.; De Vita, M.; Garramone, B.; Giannico, F.; Niccoli, G.; Biondi-Zoccai, G.G.; Schiavoni, G.; Mongiardo, R.; Crea, F. Manual thrombus-aspiration improves myocardial reperfusion: the randomized evaluation of the effect of mechanical reduction of distal embolization by thrombus-aspiration in primary and rescue angioplasty (REMEDIA) trial. J. Am. Coll. Cardiol., 2005, 46, 371.
62. Silva-Orrego, P.; Colombo, P.; Bigi, R.; Gregori, D.; Delgado, A.; Salvade, P.; Oreglia, J.; Orrico, P.; de Biase, A.; Piccalo, G.; Bossi, I.; Klugmann, S. Thrombus aspiration before primary angioplasty improves myocardial reperfusion in acute myocardial infarction: the DEAR-MI (Dethrombosis to Enhance Acute Reperfusion in Myocardial Infarction) study. J. Am. Coll. Cardiol., 2006, 48, 1552.
63. Svilaas, T.; Vlaar, P.J.; van der Horst, I.C.; Diercks, G.F.; de Smet, B.J.; van den Heuvel, A.F.; Anthonio, R.L.; Jessurun, G.A.; Tan, E.S.; Suurmeijer, A.J.; Zijlstra, F. Thrombus aspiration during primary percutaneous coronary intervention. N. Engl. J. Med., 2008, 358, 557.
64. Kaltoft, A.; Bottcher, M.; Nielsen, S.S.; Hansen, H.H.; Terkelsen, C.; Maeng, M.; Kristensen, J.; Thuesen, L.; Krusell, L.R.; Kristensen, S.D.; Andersen, H.R.; Lassen, J.F.; Rasmussen, K.; Rehling, M.; Nielsen, T.T.; Botker, H.E. Routine thrombectomy in percutaneous coronary intervention for acute ST-segment-elevation myocardial infarction: a randomized, controlled trial. Circulation, 2006, 114, 40.
65. Ali, A.; Cox, D.; Dib, N.; Brodie, B.; Berman, D.; Gupta, N.; Browne, K.; Iwaoka, R.; Azrin, M.; Stapleton, D.; Setum, C.; Popma, J. Rheolytic thrombectomy with percutaneous coronary intervention for infarct size reduction in acute myocardial infarction: 30-day results from a multicenter randomized study. J. Am. Coll. Cardiol., 2006, 48, 244.
66. Stone, G.W.; Cox, D.A.; Babb, J.; Nukta, D.; Bilodeau, L.; Cannon, L.; Stuckey, T.D.; Hermiller, J.; Cohen, E.A.; Low, R.; Bailey, S.R.; Lansky, A.J.; Kuntz, R.E. Prospective, randomized evaluation of thrombectomy prior to percutaneous intervention in diseased saphenous vein grafts and thrombus-containing coronary arteries. J. Am. Coll. Cardiol., 2003, 42, 2007.
67. Vlaar, P.J.; Svilaas, T.; van der Horst, I.C.; Diercks, G.F.; Fokkema, M.L.; de Smet, B.J.; van den Heuvel, A.F.; Anthonio, R.L.; Jessurun, G.A.; Tan, E.S.; Suurmeijer, A.J.; Zijlstra, F. Cardiac death and reinfarction after 1 year in the Thrombus Aspiration during Percutaneous coronary intervention in Acute myocardial infarction Study (TAPAS): a 1-year follow-up study. Lancet, 2008, 371, 1915.
68. Gessi, S.; Merighi, S.; Varani, K.; Leung, E.; Mac Lennan, S.; Borea, P.A. The A3 adenosine receptor: an enigmatic player in cell biology. Pharmacol. Ther., 2008, 117, 123.
69. Assali, A.R.; Sdringola, S.; Ghani, M.; Denkats, A.E.; Yepes, A.; Hanna, G.P.; Schroth, G.; Fujise, K.; Anderson, H.V.; Smalling, R.W.; Rosales, O.R. Intracoronary adenosine administered during percutaneous intervention in acute myocardial infarction and reduction in the incidence of "no reflow" phenomenon. Catheter Cardiovasc. Interv., 2000, 51, 27.
70. Sdringola, S.; Assali, A.; Ghani, M.; Yepes, A.; Rosales, O.; Schroth, G.W.; Fujise, K.; Anderson, H.V.; Smalling, R.W. Adenosine use during aortocoronary vein graft interventions reverses but does not prevent the slow-no reflow phenomenon. Catheter Cardiovasc. Interv., 2000, 51, 394.
71. Vijayalakshmi, K.; Whittaker, V.J.; Kunadian, B.; Graham, J.; Wright, R.A.; Hall, J.A.; Sutton, A.; de Belder, M.A. Prospective, randomised, controlled trial to study the effect of intracoronary injection of verapamil and adenosine on coronary blood flow during percutaneous coronary intervention in patients with acute coronary syndromes. Heart, 2006, 92, 1278.
72. Fischell, T.A.; Carter, A.J.; Foster, M.T.; Hempsall, K.; DeVries, J.; Kim, D.H.; Kloostra, A. Reversal of "no reflow" during vein graft stenting using high velocity boluses of intracoronary adenosine. Cathet. Cardiovasc. Diagn., 1998, 45, 360.
73. Mahaffey, K.W.; Puma, J.A.; Barbagelata, N.A.; DiCarli, M.F.; Leesar, M.A.; Browne, K.F.; Eisenberg, P.R.; Bolli, R.; Casas, A.C.; Molina-Viamonte, V.; Orlandi, C.; Blevins, R.; Gibbons, R.J.; Califf, R.M.; Granger, C.B. Adenosine as an adjunct to thrombolytic therapy for acute myocardial infarction: results of a multicenter, randomized, placebo-controlled trial: the Acute Myocardial Infarction STudy of ADenosine (AMISTAD) trial. J. Am. Coll. Cardiol., 1999, 34, 1711.
74. de Lemos, J.A.; Antman, E.M.; Gibson, C.M.; McCabe, C.H.; Giugliano, R.P.; Murphy, S.A.; Coulter, S.A.; Anderson, K.; Scherer, J.; Frey, M.J.; Van Der Wieken, R.; Van De Werf, F.; Braunwald, E. Abciximab improves both epicardial flow and myocardial reperfusion in ST-elevation myocardial infarction. Observations from the TIMI 14 trial. Circulation, 2000, 101, 239.
75. Petronio, A.S.; Rovai, D.; Musumeci, G.; Baglini, R.; Nardi, C.; Limbruno, U.; Palagi, C.; Volterrani, D.; Mariani, M. Effects of abciximab on microvascular integrity and left ventricular functional recovery in patients with acute infarction treated by primary coronary angioplasty. Eur. Heart J., 2003, 24, 67.
76. Neumann, F.J.; Blasini, R.; Schmitt, C.; Alt, E.; Dirschinger, J.; Gawaz, M.; Kastrati, A.; Schomig, A. Effect of glycoprotein IIb/IIIa receptor blockade on recovery of coronary flow and left ventricular function after the placement of coronary-artery stents in acute myocardial infarction. Circulation, 1998, 98, 2695.
77. Mak, K.H.; Challapalli, R.; Eisenberg, M.J.; Anderson, K.M.; Califf, R.M.; Topol, E.J. Effect of platelet glycoprotein IIb/IIIa receptor inhibition on distal embolization during percutaneous revascularization of aortocoronary saphenous vein grafts. EPIC Investigators. Evaluation of IIb/IIIa platelet receptor antagonist 7E3 in Preventing Ischemic Complications. Am. J. Cardiol., 1997, 80, 985.
78. Hillegass, W.B.; Dean, N.A.; Liao, L.; Rhinehart, R.G.; Myers, P.R. Treatment of no-reflow and impaired flow with the nitric oxide donor nitroprusside following percutaneous coronary interventions: initial human clinical experience. J. Am. Coll. Cardiol., 2001, 37, 1335.
79. Wang, H.J.; Lo, P.H.; Lin, J.J.; Lee, H.; Hung, J.S. Treatment of slow/ no-reflow phenomenon with intracoronary nitroprusside injection in primary coronary intervention for acute myocardial infarction. Catheter Cardiovasc. Interv., 2004, 63, 171.
80. Pasceri, V.; Pristipino, C.; Pelliccia, F.; Granatelli, A.; Speciale, G.; Roncella, A.; Pironi, B.; Capasso, M.; Richichi, G. Effects of the nitric oxide donor nitroprusside on no-reflow phenomenon during coronary interventions for acute myocardial infarction. Am. J. Cardiol., 2005, 95, 1358.
81. Amit, G.; Cafri, C.; Yaroslavtsev, S.; Fuchs, S.; Paltiel, O.; Abu-Ful, A.; Weinstein, J.M.; Wolak, A.; Ilia, R.; Zahger, D. Intracoronary nitroprusside for the prevention of the no-reflow phenomenon after primary percutaneous coronary intervention in acute myocardial infarction. A randomized, double-blind, placebo-controlled clinical trial. Am. Heart J., 2006, 152, 887 e9.
82. Hang, C.L.; Wang, C.P.; Yip, H.K.; Yang, C.H.; Guo, G.B.; Wu, C.J.; Chen, S.M. Early administration of intracoronary verapamil improves myocardial perfusion during percutaneous coronary interventions for acute myocardial infarction. Chest, 2005, 128, 2593.
83. Michaels, A.D.; Appleby, M.; Otten, M.H.; Dauterman, K.; Ports, T.A.; Chou, T.M.; Gibson, C.M. Pretreatment with intragraft verapamil prior to percutaneous coronary intervention of saphenous vein graft lesions: results of the randomized, controlled vasodilator prevention on no-reflow (VAPOR) trial. J. Invasive Cardiol., 2002, 14, 299.
84. Kaplan, B.M.; Benzuly, K.H.; Kinn, J.W.; Bowers, T.R.; Tilli, F.V.; Grines, C.L.; O'Neill, W.W.; Safian, R.D. Treatment of no-reflow in degenerated saphenous vein graft interventions: comparison of intracoronary verapamil and nitroglycerin. Cathet. Cardiovasc. Diagn., 1996, 39, 113.
85. Werner, G.S.; Lang, K.; Kuehnert, H.; Figulla, H.R. Intracoronary verapamil for reversal of no-reflow during coronary angioplasty for acute myocardial infarction. Catheter Cardiovasc. Interv., 2002, 57, 444.
86. Weyrens, F.J.; Mooney, J.; Lesser, J.; Mooney, M.R. Intracoronary diltiazem for microvascular spasm after interventional therapy. Am. J. Cardiol., 1995, 75, 849.
87. Fischell, T.; Haller, S.; Ashraf, K. Intragraft nicardipine prophylaxis to prevent no-reflow in triple-vessel saphenous vein graft intervention. J. Invasive Cardiol., 2005, 17, 334.
88. Lambert, C.R.; Pepine, C.J. Effects of intravenous and intracoronary nicardipine. Am. J. Cardiol., 1989, 64, 8H.
89. Kaufmann, P.; Vassalli, G.; Utzinger, U.; Hess, O.M. Coronary vasomotion during dynamic exercise: influence of intravenous and intracoronary nicardipine. J. Am. Coll. Cardiol., 1995, 26, 624.
90. Fugit, M.D.; Rubal, B.J.; Donovan, D.J. Effects of intracoronary nicardipine, diltiazem and verapamil on coronary blood flow. J. Invasive Cardiol., 2000, 12, 80.
91. Huang, R.I.; Patel, P.; Walinsky, P.; Fischman, D.L.; Ogilby, J.D.; Awar, M.; Frankil, C.; Savage, M.P. Efficacy of intracoronary nicardipine in the treatment of no-reflow during percutaneous coronary intervention. Catheter Cardiovasc. Interv., 2006, 68, 671.
92. White, C.J.; Ramee, S.R.; Collins, T.J.; Escobar, A.E.; Karsan, A.; Shaw, D.; Jain, S.P.; Bass, T.A.; Heuser, R.R.; Teirstein, P.S.; Bonan, R.; Walter, P.D.; Smalling, R.W. Coronary thrombi increase PTCA risk. Angioscopy as a clinical tool. Circulation, 1996, 93, 253.
93. Miura, T.; Miki, T. ATP-sensitive K+ channel openers: old drugs with new clinical benefits for the heart. Curr. Vasc. Pharmacol., 2003, 1, 251.
94. Ono, H.; Osanai, T.; Ishizaka, H.; Hanada, H.; Kamada, T.; Onodera, H.; Fujita, N.; Sasaki, S.; Matsunaga, T.; Okumura, K. Nicorandil improves cardiac function and clinical outcome in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention: role of inhibitory effect on reactive oxygen species formation. Am. Heart J., 2004, 148, E15.
95. Lim, S.Y.; Bae, E.H.; Jeong, M.H.; Kang, D.G.; Lee, Y.S.; Kim, K.H.; Lee, S.H.; Yoon, K.H.; Hong, S.N.; Park, H.W.; Hong, Y.J.; Kim, J.H.; Kim, W.; Ahn, Y.K.; Cho, J.G.; Park, J.C.; Kang, J.C. Effect of combined intracoronary adenosine and nicorandil on no-reflow phenomenon during percutaneous coronary intervention. Circ. J., 2004, 68, 928.
96. Tsubokawa, A.; Ueda, K.; Sakamoto, H.; Iwase, T.; Tamaki, S. Effect of intracoronary nicorandil administration on preventing no-reflow/slow flow phenomenon during rotational atherectomy. Circ. J., 2002, 66, 1119.
97. Ota, S.; Nishikawa, H.; Takeuchi, M.; Nakajima, K.; Nakamura, T.; Okamoto, S.; Setsuda, M.; Makino, K.; Yamakado, T.; Nakano, T. Impact of nicorandil to prevent reperfusion injury in patients with acute myocardial infarction: Sigmart Multicenter Angioplasty Re-vascularization Trial (SMART). Circ. J., 2006, 70, 1099.
98. Yanagisawa, M.; Kurihara, H.; Kimura, S.; Tomobe, Y.; Kobayashi, M.; Mitsu8i, Y.; Yazaki, Y.; Goto, K.; Masaki, T. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature, 1988, 332, 411.
99. Inoue, A.; Yanagisawa, M.; Kimura, S.; Kasuya, Y.; Miyauchi, T.; Goto, K.; Masaki, T. The human endothelin family: three structurally and pharmacologically distinct isopeptides predicted by three separate genes. Proc. Natl. Acad. Sci. USA, 1989, 86, 2863.
100. Macdonald, R.L.; Pluta, R.M.; Zhang, J.H. Cerebral vasospasm after subarachnoid hemorrhage: the emerging revolution. Nat. Clin. Pract. Neurol., 2007, 3, 256.
101. Keeley, E.C.; Velez, C.A.; O'Neill, W.W.; Safian, R.D. Long-term clinical outcome and predictors of major adverse cardiac events after percutaneous interventions on saphenous vein grafts. J. Am. Coll. Cardiol., 2001, 38, 659.
102. Baim, D.S.; Wahr, D.; George, B.; Leon, M.B.; Greenberg, J.; Cutlip, D.E.; Kaya, U.; Popma, J.J.; Ho, K.K.; Kuntz, R.E. Randomized trial of a distal embolic protection device during percutaneous intervention of saphenous vein aorto-coronary bypass grafts. Circulation, 2002, 105, 1285.
103. Stone, G.W.; Rogers, C.; Hermiller, J.; Feldman, R.; Hall, P.; Haber, R.; Masud, A.; Cambier, P.; Caputo, R.P.; Turco, M.; Kovach, R.; Brodie, B.; Herrmann, H.C.; Kuntz, R.E.; Popma, J.J.; Ramee, S.; Cox, D.A. Randomized comparison of distal protection with a filter-based catheter and a balloon occlusion and aspiration system during percutaneous intervention of diseased saphenous vein aorto-coronary bypass grafts. Circulation, 2003, 108, 548.
104. Moreno, P.R.; Palacios, I.F.; Leon, M.N.; Rhodes, J.; Fuster, V.; Fallon, J.T. Histopathologic comparison of human coronary in-stent and post-balloon angioplasty restenotic tissue. Am. J. Cardiol., 1999, 84, 462.
105. Kearney, M.; Pieczek, A.; Haley, L.; Losordo, D.W.; Andres, V.; Schainfeld, R.; Rosenfield, K.; Isner, J.M. Histopathology of in-stent restenosis in patients with peripheral artery disease. Circulation, 1997, 95, 1998.
106. Sano, K.; Mintz, G.S.; Carlier, S.G.; Fujii, K.; Yasuda, T.; Kimura, M.; Costa, J.R., Jr.; Costa, R.A.; Lui, J.; Weisz, G.; Moussa, I.; Dangas, G.D.; Mehran, R.; Lansky, A.J.; Kreps, E.M.; Collins, M.; Stone, G.W.; Moses, J.W.; Leon, M.B. Intravascular ultrasonic differences between aorto-ostial and shaft narrowing in saphenous veins used as aortocoronary bypass grafts. Am. J. Cardiol., 2006, 97, 1463.
107. Carrozza, J.P., Jr.; Mumma, M.; Breall, J.A.; Fernandez, A.; Heyman, E.; Metzger, C. Randomized evaluation of the TriActiv balloon-protection flush and extraction system for the treatment of saphenous vein graft disease. J. Am. Coll. Cardiol., 2005, 46, 1677.
108. Mauri, L.; Cox, D.; Hermiller, J.; Massaro, J.; Wahr, J.; Tay, S.W.; Jonas, M.; Popma, J.J.; Pavliska, J.; Wahr, D.; Rogers, C. The PROXIMAL trial: proximal protection during saphenous vein graft intervention using the Proxis Embolic Protection System: a randomized, prospective, multicenter clinical trial. J. Am. Coll. Cardiol., 2007, 50, 1442.
109. Halkin, A.; Masud, A.Z.; Rogers, C.; Hermiller, J.; Feldman, R.; Hall, P.; Haber, R.H.; Cambier, P.A.; Caputo, R.P.; Turco, M.; Kovach, R.; Brodie, B.; Herrmann, H.C.; Kuntz, R.E.; Popma, J.J.; Ramee, S.; Cox, D.A.; Mehran, R.; Stone, G.W. Six-month outcomes after percutaneous intervention for lesions in aortocoronary saphenous vein grafts using distal protection devices: results from the FIRE trial. Am. Heart J., 2006, 151, 915. e1.
110. von Korn, H.; Yu, J.; Huegl, B.; Wagner, A.; Ohlow, M.; Lauer, B. Safety and efficacy of a new filter-based protection system for aorto-coronary bypass graft interventions: the ev3 Spider device. J. Invasive Cardiol., 2005, 17, 352.
111. Blackman, D.J.; Choudhury, R.P.; Banning, A.P.; Channon, K.M. Failure of the Symbiot PTFE-covered stent to reduce distal embolization during percutaneous coronary intervention in saphenous vein grafts. J. Invasive Cardiol., 2005, 17, 609.
112. Stankovic, G.; Colombo, A.; Presbitero, P.; van den Branden, F.; Inglese, L.; Cernigliaro, C.; Niccoli, L.; Bartorelli, A.L.; Rubartelli, P.; Reifart, N.; Heyndrickx, G.R.; Saunamaki, K.; Morice, M.C.; Sgura, F.A.; Di Mario, C. Randomized evaluation of polytetrafluoroethylene-covered stent in saphenous vein grafts: the Randomized Evaluation of polytetrafluoroethylene COVERed stent in Saphenous vein grafts (RECOVERS) Trial. Circulation, 2003, 108, 37.
113. Roffi, M.; Mukherjee, D.; Chew, D.P.; Bhatt, D.L.; Cho, L.; Robbins, M.A.; Ziada, K.M.; Brennan, D.M.; Ellis, S.G.; Topol, E.J. Lack of benefit from intravenous platelet glycoprotein IIb/IIIa receptor inhibition as adjunctive treatment for percutaneous interventions of aortocoronary bypass grafts: a pooled analysis of five randomized clinical trials. Circulation, 2002, 106, 3063.
114. Jonas, M.; Stone, G.W.; Mehran, R.; Hermiller, J.; Feldman, R.; Herrmann, H.C.; Cox, D.A.; Kuntz, R.E.; Popma, J.J.; Rogers, C. Platelet glycoprotein IIb/IIIa receptor inhibition as adjunctive treatment during saphenous vein graft stenting: differential effects after randomization to occlusion or filter-based embolic protection. Eur. Heart J., 2006, 27, 920.